EC psychology and psychiatry最新文献

筛选

英文中文

Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse? 长期摄入咖啡因增加D2/D3受体是否对可卡因滥用的DRD2 A1等位基因携带者有益?

EC psychology and psychiatry Pub Date : 2019-04-15

Kenneth Blum, David Baron, Rajendra D Badgaiyan, Mark S Gold

引用次数: 0

Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. 亲多巴胺调节剂(KB220PAM)联合纳曲酮预防阿片类药物使用障碍复发的证据分析。

EC psychology and psychiatry Pub Date : 2018-08-01 Epub Date: 2018-07-30

Kenneth Blum, Edward J Modestino, Rajendra D Badgaiyan, David Baron, Panayotis K Thanos, Igor Elman, David Siwicki, Marcelo Febo, Mark S Gold

{"title":"Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.","authors":"Kenneth Blum, Edward J Modestino, Rajendra D Badgaiyan, David Baron, Panayotis K Thanos, Igor Elman, David Siwicki, Marcelo Febo, Mark S Gold","doi":"","DOIUrl":"","url":null,"abstract":"Blum's laboratory first showed the benefits of naloxone or narcotic antagonists in the treatment of alcohol dependence. This seminal work published in Nature in the early 70's, in conjunction with many other studies, later served as the basis for the development of the narcotic antagonist (NTX) now used to treat both alcohol and opioid dependence. In 2006 an extended-release injectable of Naltrexone (XR-NTX) was approved by the FDA. Naltrexone is a relatively weak antagonist of κ- and δ-receptors and is also a potent μ-receptor antagonist. Dosages of naltrexone that effectively reduce opioid and alcohol consumption also actively block μ-receptors, but chronically down-regulate mesolimbic dopamine release. While studies show benefit especially in the short term, there is ongoing evidence that the retention and compliance with NTX are not sufficient to characterize adherence as high. However, extended-release NTX opioid treatment is associated with superior outcomes including less likely relapse (defined as daily use), and much longer time to relapse despite higher rates of concurrent non-opioid substance use like cocaine. Regarding long-term extended-release injectable (XR-NTX) for opioid dependence; there was higher compliance with Opioid Use Disorder (OUD) than for Alcohol Use Disorder (AUD.). Consideration of modalities in combination with XR-NTX is imperative. Research by Blum., et al. showed that a combination of Naltrexone and a pro-dopamine regulator neuro-nutrient (KB220) significantly prevented opioid relapse. Thus, early identification of addiction vulnerability with the Genetic Addiction Risk Score (GARS™) a panel of polymorphic risk alleles from ten reward circuitry genes will provide valuable information especially as it relates to genetically guided therapy with the KB220 neuro nutrient termed 'Precision Addiction Management\".","PeriodicalId":72862,"journal":{"name":"EC psychology and psychiatry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226033/pdf/nihms-991063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36665659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页